NFE2L2 and prostate carcinoma: The treatment of prostate cancer cells with FN1 ((3E,5E)-3,5-bis(pyridin-2/3/4-methylene)-tetrahydrothiopyran-4-one), a synthetic analog of curcumin (Figure 1k), has increased the level of Nrf2, decreased the level of Keap1, and activated the Nrf2/ARE signaling pathway.